... Abstract Background: The pathogenesis of anemia in chronic kidney disease (CKD) could be multifactorial. In recent animal studies, hepcidin knockout (KO) mice with adenine-induced CKD did not exhibit anemia and iron deficiency. Hepcidin has emerged as a major player in the development...

... Abstract At the cellular level, defects in Fanconi anemia (FA) genes manifest themselves ashypersensitivity to DNA damaging agents which can be assessed by increased chromosomebreakage and cell cycle changes. As long-term manifestations of cellular genetic instability,FA patients are at high...

... Abstract Background: Hypoxia-inducible factor (HIF) stabilizers, also known as inhibitors of HIF prolyl hydroxylase domain (PHD) inhibitors enzymes, are novel small-molecule agents to treat renal anemia. They increase endogenous erythropoietin (EPO) production by stabilizing HIF...

... hormones. Therefore, it is possible that the responsiveness to erythropoiesis-stimulating agent (ESA) and the ability to utilize iron for erythropoiesis differ between elderly and nonelderly CKD patients. Indeed, in an observational study on the relationship between anemia management and adverse events...

... and iron for maintaining target Hb levels in these patients are not well established. Thus, from the perspective of long-term survival in chronic kidney disease patients, it is necessary to treat anemia with appropriate doses of ESAs and an iron that can induce physiological erythropoiesis. Renal...

... Abstract Background: Carnitine deficiency is a common condition in hemodialysis patients. There have been numerous reports on the efficacy of levocarnitine therapy in hemodialysis patients, including different views. Reported effects of levocarnitine are: (1) improvement of renal anemia, (2...

... Abstract Normal iron metabolism is essential for effective hemoglobin (Hb) production in the management of renal anemia. Considering that studies regarding the optimal Hb levels predated the creation of the iron management indices found in the treatment guidelines for hemodialysis (HD) patients...

.... In particular, posttransplantation anemia (PTA) is often protracted, which could be related to a variety of factors, including the renal function status, graft rejection episodes, and infectious causes. PTA occurs in about 30-40% of transplant recipients, and is known to affect the function of the transplanted...

... Abstract Thiamine-responsive megaloblastic anemia (TRMA) syndrome (OMIM No. 249270) is an autosomal recessive disorder and an example of a rare form of monogenic diabetes coexisting with anemia and deafness. The disease is caused by mutations in the SLC19A2 gene encoding the high-affinity...

... Abstract Glomerulonephritis (GN) remains a major cause of morbidity and mortality in chronic kidney disease (CKD). Our study aimed to investigate the prevalence of anemia, abnormal serum intact parathyroid hormone (iPTH), calcium, and phosphorus in a Chinese patient population with primary GN...

... Abstract Anemia is a common complication of patients receiving peritoneal dialysis (PD) but has been little studied compared to other chronic kidney disease (CKD) populations. A number of factors can affect its severity or response to erythropoiesis-stimulating agents (ESA). Some, such as iron...

... Abstract Patients with advanced chronic kidney disease are characterized by an imbalancebetween pro- and antioxidant factors, and increased oxidative stress has been associated withcomplications of end-stage renal disease such as atherosclerosis, β₂-microglobulin amyloidosisand anemia...

... Abstract After almost 20 years, anemia in chronic kidney disease (CKD) and its treatmentremain the focus of multiple questions for clinicians and investigators. The optimal hemoglobin(Hb) for patients with CKD is controversial and different targets are probably requiredfor different populations...

... Abstract In a field that embraces multiple aspects of both clinical and basic research and thatmoves impressively fast, any answers to the questions why, what and how can we learn froma rare disease like Fanconi anemia (FA) must remain tentative and preliminary. However,there are very...

... Abstract We present the clinical case histories of 7 patients with Fanconi Anemia (FA) in orderto illustrate the widely divergent phenotypes and clinical courses of the disease. Moreover,these case histories demonstrate that androgen therapy and hematopoietic stem cell transplantationare...

... Abstract The recessive disease Fanconi anemia (FA) is a prototype chromosome instability syndromewhich shows a high level of spontaneous and induced chromosomal aberrations incombination with a significantly increased cancer risk. Thus, the underlying defect must bedirectly or indirectly...

... Abstract Fanconi anemia patients have a high risk for bone marrow failure, aplastic anemia,myelodysplastic syndrome, and acute myeloid leukemia. Many FA patients acquire chromosomalaberrations in their bone marrow (BM) cells. The significance and predictive value ofthese somatic aberrations...